2021
Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors
Davies M, Russo A. Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors. Current Cancer Research 2021, 139-173. DOI: 10.1007/978-3-030-74028-3_7.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune related adverse eventsImmune-related adverse eventsRelated adverse eventsCheckpoint inhibitorsAdverse eventsAnti-PD-1/PD-L1Life-threatening organ failureOrgan systemsManagement of toxicitiesCourse of treatmentDegree of severityPD-L1Organ failureGrade severityRisk factorsClinical practiceImmune systemCancer subtypesModern oncologyCancer treatmentOrgan pathophysiologyBasis of toxicityPresent signsToxicity
2020
NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting.
Adelson K, Herbst R, Peterson P, Ingram M, Oliver B, Agrawal T, Davies M, Rudell E. NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting. Journal Of Clinical Oncology 2020, 38: 7054-7054. DOI: 10.1200/jco.2020.38.15_suppl.7054.Peer-Reviewed Original ResearchCheckpoint inhibitor therapyReasonable treatment optionMore side effectsLung cancer patientsCancer care settingsPatient-centered careTreatment decision processNational Quality ForumInhibitor therapyPatient-centric careCancer patientsTreatment optionsTreatment choicePost-intervention interviewsPatientsSide effectsPractice settingsQuality ForumSDM skillsHealthcare decisionsCareSDM processGreater improvementCliniciansTeam members
2019
Nursing Considerations for Patients Treated with Targeted Therapies
Goodwin K, Davies M. Nursing Considerations for Patients Treated with Targeted Therapies. 2019, 105-120. DOI: 10.1007/978-3-030-16550-5_9.Peer-Reviewed Original ResearchThe Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer
Andrews S, Davies M. The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. 2019, 65-84. DOI: 10.1007/978-3-030-16550-5_7.Peer-Reviewed Original Research
2012
Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx.
Acevedo-Gadea C, Baumgart M, Wang Z, Deshpande H, Davies M, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Prognostic significance of the AJCC staging in patients with squamous cell carcinoma of the oropharynx. Journal Of Clinical Oncology 2012, 30: 5529-5529. DOI: 10.1200/jco.2012.30.15_suppl.5529.Peer-Reviewed Original ResearchSquamous cell carcinomaOP cancerOverall survivalHuman papillomavirusOral cavityAJCC stagePrognostic significanceCell carcinomaStage IFrequency of HPVNeck squamous cell carcinomaCurrent AJCC systemEnd Results registryKaplan-Meier methodEpidemiology of headL. PatientsPrognostic impactAJCC stagingOropharyngeal cancerPrognostic factorsStage IVBSurveillance EpidemiologyAJCC systemPatient populationClinical behaviorInfluence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck.
Baumgart M, Acevedo-Gadea C, Wang Z, Buta E, Davies M, Deshpande H, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2012, 30: 5532-5532. DOI: 10.1200/jco.2012.30.15_suppl.5532.Peer-Reviewed Original ResearchPoor prognostic factorSquamous cell carcinomaExtracapsular extensionOral cavityOverall survivalPrognostic factorsCell carcinomaIndependent poor prognostic factorNeck squamous cell carcinomaCox proportional hazards modelSignificant OS differenceSquamous cell cancerProportional hazards modelPrognostic impactSurveillance EpidemiologyCell cancerPoor outcomeKaplan-MeierECE statusOS differenceAJCC manualEligibility criteriaHazards modelPrimary siteSurvival curves
2008
Successful desensitization with cetuximab (CET) after hypersensitivity reaction (HSR) to panitumumab (PAN) and CET in patients (pts) with metastatic colorectal cancer (mCRC)
Shah M, Hotchkiss S, Shanley J, Davies M, Ferencz T, Syrigos K, Syrigos K, Saif M. Successful desensitization with cetuximab (CET) after hypersensitivity reaction (HSR) to panitumumab (PAN) and CET in patients (pts) with metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2008, 26: 15092-15092. DOI: 10.1200/jco.2008.26.15_suppl.15092.Peer-Reviewed Original Research
2004
A Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer
Murren J, Gerson S, Kummar S, Davies M, Remick S, Chu E, Karsten V, Sznol M. A Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer. Journal Of Clinical Oncology 2004, 22: 2060-2060. DOI: 10.1200/jco.2004.22.14_suppl.2060.Peer-Reviewed Original ResearchA Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer
Murren J, Gerson S, Kummar S, Davies M, Remick S, Chu E, Karsten V, Sznol M. A Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer. Journal Of Clinical Oncology 2004, 22: 2060-2060. DOI: 10.1200/jco.2004.22.90140.2060.Peer-Reviewed Original Research
2001
Irinotecan and Taxane Combinations for Non–Small-Cell Lung Cancer
Murren J, Davies M. Irinotecan and Taxane Combinations for Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2001, 2: s20-s25. PMID: 14725726, DOI: 10.3816/clc.2001.s.004.Peer-Reviewed Original ResearchNon-small cell lung cancerLung cancerAdvanced non-small cell lung cancerDay 1Treatment of NSCLCWeekly scheduleLow-grade gastrointestinal toxicitySmall cell lung cancerPaclitaxel-containing regimenDoses of docetaxelDose-limiting toxicityCell lung cancerEvaluable patientsNonhematologic toxicityStable diseaseGastrointestinal toxicityTaxane combinationsPartial responseProgressive diseaseMild diarrheaPreclinical modelsAdditive cytotoxicityToxicity profileTreatment scheduleChemotherapy